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Introduction 
Back pain is the most common and costliest musculoskeletal condition in the United 
Kingdom (UK), affecting 30% of the adult population annually [1,2]. It is associated 
with functional limitation, depression and anxiety, and thus reduced quality of life 
(QoL) [3]. In addition, back pain is the leading cause of productivity loss due to 
absence from work and is associated with significant healthcare resource use [4]. 
The annual cost of back pain for investigations, treatment, and loss of productivity 
resulting from disability, has been estimated to be £1.6 billion. Costs relating to 
services provided in the private sector account for 35% of this figure [4].   
 
Due to the considerable personal and economic burden of back pain, new and 
innovative ways of delivering clinically and cost-effective measures are constantly 
sought by healthcare providers. In the National Health Service (NHS), 
Musculoskeletal Clinical Assessment Services (MCAS) have been developed to 
manage back pain. Here, Advanced Physiotherapy Practitioners triage referrals and 
manage patients along locally implemented pathways. A number of benefits of this 
type of service have been reported including: a reduction in unnecessary referrals to 
secondary care [5,6]; enhanced patient satisfaction [7,8] improved surgical 
conversion rates [7], and improved patient reported outcomes including generic 
health status and pain [8].  
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In 2011, over 80 000 of the 2.5 million clients of one UK private healthcare provider 
were treated for back pain. In response to the large number of people requiring 
assessment and treatment of back pain, a specialised service was required. Thus, 
the MCAS model was adapted for the private sector and a Case Management 
Service (CMS), led by physiotherapists, was developed. In contrast to the MCAS 
service, the CMS was telephone based.  
 
The aim of the CMS was for clients with back pain to receive fast access to advice 
and the appropriate treatment at the right time. Client assessment was undertaken 
by a Case Manager using a detailed telephone assessment along with the referring 
physiotherapist’s documentation for the objective assessment. The Case Manager, 
based within the private insurance provider setting, had an overview of the client’s 
treatment pathway, insurance policy benefits and clinical presentations. Their role 
was to facilitate early access to consultants, when necessary; reduce unnecessary 
diagnostics and surgical referrals, as recommended in the Musculoskeletal Services 
Framework [9]; and reduce over-treatment with non-evidence based practice. It was 
therefore anticipated that the CMS should improve patient outcomes while potentially 
decreasing the total overall cost of treatment.  
 
However, CMS is a relatively new area for musculoskeletal physiotherapists to be 
involved in within the UK. Moreover, the clinical and cost-effectiveness of a 
physiotherapy led CMS in the UK private sector has not been documented. Due to 
differences between private and public healthcare sectors in terms of access and 
service delivery, the NHS based literature may not be transferable to the private 
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sector. Therefore, the aim of this study was to evaluate the clinical effectiveness and 
resource use of a UK private sector, Case Management Service.  
 
Methodology 
Design  
An observational cohort study was undertaken to investigate the aim of this study. 
This was based on prospective data collection of patient reported outcome measures 
(PROMs) and data collection from an existing administrative health database of a UK 
private healthcare provider. This study is presented in accordance with SQUIRE 
guidelines [10]. Ethical Approval was obtained for the study from the Manchester 
Metropolitan University Ethics Committee. Additionally, management approval was 
obtained from the national provider of private healthcare. 
 
Participants 
Consecutive referrals to the CMS over a three-month period were entered into the 
evaluation. Participants were identified through their medical records. They were 
included in the study if they had previously received a minimum of six sessions of 
therapy and had failed to respond positively to treatment prior to referral to the CMS. 
The participants were aged over 18 years with no upper age limit. Participants who 
were not able to communicate in English, or demonstrated difficulties with telephone 
communication, were excluded from the study. Participants were also excluded from 
pre and post PROM collection if at initial assessment they required advice only and 
no ongoing input, however, they were included in the satisfaction survey.  
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Outcome measures 
Functional ability was examined using the Patient Specific Functional Scale (PSFS). 
This has been designed for assessing functional change in patients with 
musculoskeletal disorders and has been found to be valid and responsive to change 
in this population [11,12]. The PSFS is scored between 0 and 10 for each activity 
that is limited by the condition for which the client is seeking treatment; 10 being no 
problems and zero being unable to perform the activity. The overall PSFS score is 
an average of all activity scores.  
 
QoL was examined, using EQ-5D-5L, a generic PROM, that has been shown to be 
reliable and valid for musculoskeletal conditions [3,13] and adopted for use by the 
UK National PROMs programme. Patient perceived improvement was assessed 
using EQ-VAS which is an integral component of the EQ-5D-5L and is recognised as 
being clinically relevant when taken alongside PROMs and patient satisfaction 
[14,15].  
 
The Consultant and Relational Empathy (CARE) measure is a patient reported 
experience measure (PREM), which examines the patient’s experience of the 
consultation process and is recommended by the Chartered Society of 
Physiotherapy (CSP) for use in physiotherapy services [13]. It measures empathy in 
the context of the therapeutic relationship during a one-on-one consultation and can 
be used to assess client satisfaction [16]. The questionnaire consists of ten 
questions concerning the performance of the therapist, and is rated on a scale from 
1 (poor) to 5 (excellent) with a maximum total score of 50 and a minimum of 10. A 
higher score indicates a greater perception of therapist empathy and satisfaction. 
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The CARE measure has been found to have face and content validity with high 
internal reliability and to be stable across different socio-economic patient groups 
[16].  
 
Cost Consequences analysis 
Cost consequences analysis, a method of economic evaluation with incremental 
costs reported separately to other outcomes [17]. The analysis was completed using 
an existing dataset extracted from an administrative database, by selecting all claims 
data (including cost of: therapies, consultant appointments, investigations and 
injections) for adults with a primary diagnosis of back or spinal pain over an 11-
month period from the total lives covered. Data was coded and anonymised for 
analysis. 
 
Procedure   
At initial assessment the Case Manager completed outcome measures: PSFS and 
EQ-5D-5L, verbally over the phone as per usual Case Management process. The 
client was then managed within the service in accordance with usual CMS pathways. 
At the point at which the client’s case was closed, repeat outcome measures: PSFS 
and EQ-5D-5L were taken and the CARE satisfaction questionnaire was distributed.  
 
Data Analysis  
Descriptive statistics were used to summarise patient demographics. Where data 
was normally distributed, means and standard deviation (SD) were used; however, 
median and interquartile range were used for non-normally distributed data. 
Changes between baseline and follow-up, for all health outcomes data were 
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assessed using Wilcoxon Signed Rank test. The significant value set was p < 0.05.  
The correlation between PSFS change and chronicity of symptoms was assessed 
using Spearman rho correlation analysis.  
 
Descriptive analysis was used for cost consequences evaluation. The analysis was 
used as a description of overall and itemised cost of resource use within back care. 
The analysis was completed for January to November 2011; pre-CMS 
implementation, and during the same period, January to November 2014; post-CMS 
implementation.  
 
Results 
One hundred and ten clients were referred to the study, 62 of whom completed the 
full set of outcome measures (Figure 1). Of the 62 participants, 43 were female. The 
mean age of the participants was 45.73 (SD 12.02) and mean chronicity of 
symptoms was 16.93 months (SD 50.64). 
 
Figure 1 around here 
 
Following CMS there was a statistically significant improvement in QoL (p < 0.0001). 
There were also significant improvements in perceived improvement score  and 
function (both p < 0.0001), following the CMS (Table 1). There was a weak 
correlation between chronicity of symptoms at point of referral and PSFS outcome (r 
= 0.201; p = 0.106).  
 
Table 1 around here 
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Patient Reported Experience Measure  
Ninety-six percent of the sample rated their Case Management experience as 
between good and excellent showing a high level of satisfaction with the CMS 
(Figure 2).  
 
Figure 2 around here 
 
Cost Consequences 
An analysis of the cost consequences data examining the total number of therapy 
sessions provided for clients between January and November in 2014, two years 
after CMS implementation, compared to January to November in 2011, prior CMS 
development are presented in Table 2. 
 
From the total number of clients in 2011, 3.12% of clients received treatment for their 
back complaint (Table 2). In 2014, whilst the total number of clients had decreased 
by 13%, the percentage of clients receiving back care increased to 3.65%, indicating 
an increase of 0.53% compared to 2011. Alongside this, the total number of 
individual therapy sessions delivered in 2014 had reduced by 53,475 compared to 
2011 (Table 2). The average number of sessions per client also reduced in 2014 
from 6.7 to 4.7 compared to 2011, a reduction in sessional average of 2 sessions per 
member. The number of clients attending a consultant appointment for their back 
care increased from 80% to 89% from 2011 to 2014 (Table 3). Referrals for MRI 
scans also increased from 18% to 23%. The total lives covered decreased slightly 
from 2011 to 2014 (Table 3). 
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Table 2 and 3 around here 
 
Discussion  
The aim of this study was to evaluate a CMS, in terms of effectiveness on health 
outcomes and patient satisfaction. It also examined the resource use of the CMS. 
The key findings were that health outcomes significantly improved following CMS 
with high levels of participant satisfaction. The CMS was also associated with 
reduced therapy resource use.  
 
It was found that the health outcomes measured, showed significant improvement in 
QoL and functional ability following CMS intervention. The minimum clinically 
important difference (MCID) for the PSFS is considered to be 2 points [18]. The 
mean change in PSFS post-CMS was 1.98, and therefore is approaching a clinically 
significant score, in addition to it being statistically significant. These findings 
contrast, in part, with the findings of Sephton et al [8], who undertook an evaluation 
of MCAS in Primary Care, which used a similar approach to the CMS approach used 
in this study. They found that there was a differential response by region treated, 
with patients with spinal pain showing less improvement in patient outcomes, than 
patients with upper or lower limb pain.  These conflicting findings may be a result of 
the CMS being developed as a specialist service for back care delivered by spinal 
specialists, whereas the MCAS was delivered for generic musculoskeletal 
conditions. It may also be due to the differences in the setting, with the Sephton et al 
[8] study being carried out in the NHS, compared to this study set within Private 
Health Care, where the setting and delivery of care may be different. Sample 
differences may also account for the conflicting findings. Sephton et al’s [8] sample 
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had only 42% in employment, whereas the large majority (70%) of the private 
healthcare participants in this study were employed. Not being in employment has 
been found to have a strong association with a risk of poor prognosis in back pain 
[19]. Analysis of the relationship between chronicity of symptoms and health 
outcomes, found no correlation between the duration of symptoms at baseline and 
improvement in QoL and function, post intervention. This contrasts to other studies 
who found increased chronicity of symptoms, to be a predictor of poor outcomes [8]. 
However, this may be related to the chronicity in this study being relatively low (17 
months) compared to other studies (45 months) [8].  
 
The CARE measure, found 96% of clients rated the CMS as good to excellent, thus 
indicating their satisfaction with the service. The CARE measure score has been 
found to be predictive of enablement and health changes following consultation 
across a wide range of chronic conditions [20]. This finding is of particular 
importance for the CMS where enablement of the client to make lifestyle changes 
such as exercise and work postures, to look after their back long term, is key to the 
intervention. The reasons for the high level of satisfaction in the current study is 
unknown. However, this may relate to CMS being provided at no additional cost to 
the client within their private health care provision. Further research is needed to 
investigate this. 
 
Cost consequences analysis was completed to describe the total average costs of 
treatment for back pain in the year before the CMS commenced and the second year 
following its implementation. This method sets out the resources used alongside 
health outcomes, allowing the decision makers to apportion their own value to the 
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results. Cost consequences analysis has the benefit of being clear to understand 
and therefore more likely to influence decision making in practice [21]. This method 
complimented the collection of PROMs and PREM for the full service evaluation, and 
should result in a clear overview of the current CMS in terms of costs associated with 
the intervention.  
 
The analysis found both increases and decreases in different aspects of resource 
use over the two periods observed, before implementation of the CMS and post 
implementation. These were most importantly, a reduction in cost on therapy 
provision, and an increased cost on MRI provision following the implementation of 
CMS. The observed reduction in sessional average by two sessions per member 
and overall costs reduction of therapies may be due to the role of the Case Manager. 
In this role, they had the ability to assess the client at an appropriate time point in 
their treatment pathway and intervene, when necessary, to potentially assist a 
quicker return to function, and avoid prolonged treatment. Despite the number of 
clients with back pain receiving therapy increasing and the average cost per session 
increasing by 16%, the total cost of therapy for back pain had still reduced from 2011 
to 2014 by £252 842 (from £10 772 875 to £10 520 034).  The percentage of clients 
with back pain receiving therapies had increased from 54% in 2011 to 62% in 2014; 
this is a positive outcome and an area for service development to align the service 
with current NICE guidance [22] which suggests that 85% of back pain is non-
specific low back pain and should be managed conservatively. 
 
It has been found that 30% of the UK population will suffer from back pain in one 
year [2]. Of these, 20% will seek GP advice, which is double the percentage of 
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clients in this study seeking treatment for back pain, 3.6%. This specific client group 
of private policy holders may account for the differences to the national UK 
population as previously mentioned. In this study, the number of clients attending a 
consultant appointment had increased from 80% in 2011 to 88% in 2014 and 
following on from this MRI scans delivered has also increased. The total lives 
covered decreased slightly from 2011 to 2014, and resource use increased by 
approximately £2 million (see table 3). This increase can be accounted for by the 
rising spend on MRI scans almost exactly. Referral for MRI had increased by 3.5% 
over the observed period. If the MRI cost is excluded in resources use, then the total 
overall spend only increased by £28 364 which equates an increase of 0.08%.  
 
There were some limitations to this study. The response rates for the clinical data 
(56%) and CARE postal questionnaire (24%) were low and, may have impacted on 
the findings of the present study. Future research should give due consideration to 
participant engagement strategies, such as follow-up telephone and email contact. 
Additionally, satisfaction questionnaire collection may benefit from an online template 
to allow a less demanding process for the respondent. This study did not investigate 
the long-term effectiveness of CMS, therefore, it is recommended that a 12-month 
follow-up for repeat outcome measures could be undertaken to assess maintenance 
of this improvement. This evaluation has provided evidence to demonstrate quality in 
healthcare, including patient satisfaction and improved patient reported outcome 
measures. Following the successful outcomes of the CMS for back care, 
consideration should be given to extending this service to other musculoskeletal 
conditions.   
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Conclusion 
The clinical and economic evaluation of a UK private sector CMS, showed the 
provision to be providing significant improvement in health outcomes in terms of 
quality of life and function, as well as delivering a service that 96% of users rated as 
good to excellent. There was also a reduction in overall therapy resource use in the 
period after the development of the CMS. This is largely due to the reduction in 
sessional average per client. These results suggest that this model of managing low 
back pain is cost-effective and provide economic benefit to insurance providers, and 
subsequently members via policy subscriptions, as well as providing a clinically 
effective pathway for back pain.  
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Table	1.	Outcome	measure	analysis	
Outcome	 Pre-intervention	
	
Post-intervention	
	
	
	 Median	 IQR	 Median	 IQR	 p-value	
EQ-5D-5L	(QoL)	
(max	1.00)	
	
0.6476														 0.21	 0.7357															 0.15	 <	0.0001	
EQ-VAS	%	
(perceived	
improvement)	
(max	100%)	
	
60	 20	 75	 21.25	 <	0.0001	
	
PSFS	(Function)	
(max	10)	
	
5	 2.10	 7			 3.05	 <	0.0001	
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Table	2.	Cost	for	provision	of	Therapies	
	 2011	 2014	 variation	
Average	lives	
covered	(Jan-Nov)	
	
2	572	874	 2	233	945	 -	338	929	(-13%)	
Individuals	
receiving	back	care	
(%)	
	
80	225	(3.12%)	 81	677	(3.65%)	 +	1452	(+0.53%)	
Total	individuals	
receiving	therapy	
as	part	of	their	
back	care	
	
44	074	(54.93%)	 51	038	(62.49%)	 +	6	964	(+7.56%)	
Total	number	of	
therapy	sessions	
provided	
	
295	779	 242	304	 -	53	475	
Average	sessions	
per	member	
	
6.7	 4.7	 -	2.0	
Average	cost	per	
session	
	
£36.42	 £43.42	 +	£6.99	
Cost	per	individual	
receiving	therapies	
	
£244.43	 £206.12	 -	£38.31	
Total	cost	of	
therapies	
£10	772	875	 £10	520	034	 					-		£252	841	
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Table	3.	Cost	for	consultations	and	MRI	
	 2011	 2014	 Variation	
Total	lives	covered	
	
2	572	874	 2	233	945	 -	338	929	
Individuals	
receiving	back	care	
from	total	lives	
covered.	
	
80	225	(3.11%)	 81	667	(3.66%)	 +	1452	(+0.5%)	
Total	individuals	
receiving	a	
Consultant	
appointment	as	
part	of	their	back	
care	
	
64	521	(80%)	 72	472	(89%)	 +	7951(+9%)	
Cost	per	individual	
receiving	
Consultant	
appointment	
	
£161	 £162	 +	£1	
Total	cost	of	
Consultant	
appointments	
	
£10	390	319	 £11	745	723	 +	£1	355	404	
Total	individuals	
investigated	with	
MRI	
	
14	637	(18%)	 19	037(23%)	 +	4	400	(+5%)	
Cost	per	individual	
investigated	with	
MRI	
	
£469.81	 £473.54	 +	£3.70	
Total	cost	of	MRI	 £6	876	704	 £9	014	798	 +	£2	138	094	
	
Individuals	
receiving	spinal	
injections	as	part	
of	their	back	care	
	
12	276	(15%)	 16	996	(21%)	 +	4	720	(+6%)	
Cost	per	individual	
receiving	Spinal	
injections	
	
£377.62	 £206.21	 -	£171.41	
Total	cost	of	Spinal	
injections	
	
£4	635	654	 £3	504	727	 -	£1	130	927	
	
	
Total	overall	cost																							
of	Back	care	
£ 96	738	398																											£	102	802	486	 £	2	109	759.58	
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Figure	1.	Recruitment	and	progress	through	study	
	
	
	
	
	
	
	
	
	
Participants	referred	into	study	
N	=	110	
Excluded	N	=	9	
Declined	N	=	3	
Baseline	outcome	measures	taken	
N	=	98	
PSFS,	EQ-5D-5L,	PIVAS	
Lost	to	follow-up												
N	=	36	
	
Follow-up	outcome	measures	taken	
N	=	62	
Case	Management	in	accordance	with	
usual	CMS	pathways	
	
	20	
	
	
	
Figure	2.	CARE	Measure	scores	following	CMS	intervention	
	
	
	
	
	
 
 
